|
Join us for an educational webinar and a conversation on Stargardt disease with AAVantgarde, a clinical-stage biotechnology company advancing gene therapies for individuals with inherited retinal diseases. During this session, Dr. Jayashree Sahni, Chief Medical Officer at AAVantgarde, will give an overview of Stargardt disease and the gene therapy research that informs the CELESTE study, AAVantgarde s Phase 1/2 interventional clinical trial for individuals with ABCA4 related Stargardt disease.Dr Sahni will also speak with Alice Cadman and explore her experiences of living with Stargardt disease.Participants will learn more about: Stargardt disease The CELESTE clinical trial, including eligibility criteria and research objectives What to expect during a gene therapy trial The experience of a person living with Stargardt disease |
